Please ensure Javascript is enabled for purposes of website accessibility

Moderna Files for FDA Approval of Its COVID Vaccine in Teens

By Todd Campbell - Jun 10, 2021 at 1:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company hopes to secure Emergency Use Authorization for its vaccine in children ages 12 to 18.

On Thursday, Moderna (MRNA 3.27%) announced it has filed for Emergency Use Authorization for its COVID-19 vaccine in adolescents from 12 to 18. If the agency gives Moderna a green light, parents will have another vaccine option beyond Pfizer (PFE -0.72%) and BioNTech's (BNTX 1.33%) vaccine, which was approved for ages 12 to 18 in May.

A teenage girl displays here vaccine sticker at a health center while wearing a mask.

Image source: Getty Images.

The coronavirus can be spread easily, and so far, over 174 million cases and 3.7 million deaths have been attributed to the disease worldwide.

Drugmakers including Moderna have developed vaccines to help prevent severe disease, and over the past few months, governments have made significant progress in vaccinating adult populations. For example, over 304 million COVID vaccine doses have been administered in the U.S., with 52% of Americans having received at least one dose.

The vaccination rate in children is lower, with only 23% of Americans under 18 having received at least one dose, but that rate should improve as more vaccines secure FDA approval. The agency expanded emergency use of Pfizer's COVID vaccine to include children over 12 last month, and a meeting of its advisory committee to discuss vaccinating adolescents is happening this week. 

Investigators observed no COVID cases in Moderna's study of patients ages 12 to 18, and safety outcomes were similar to those for adults, suggesting the vaccine could win emergency approval soon.

Todd Campbell has no position in any of the stocks mentioned. His clients may or may not have positions in the companies mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$176.78 (3.27%) $5.60
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$49.75 (-0.72%) $0.36
BioNTech SE Stock Quote
BioNTech SE
BNTX
$162.48 (1.33%) $2.13

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.